ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Nov 4, 2024 · CIK: 1715925
Sentiment: neutral
Topics: sec-filing, 6-K, press-release
TL;DR
IPA files 6-K, press release attached - check it for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on November 4, 2024, to report a press release dated November 4, 2024. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release itself.
Why It Matters
This filing indicates that ImmunoPrecise Antibodies Ltd. is providing an update to the SEC, likely containing information relevant to investors, though the specific details are within the attached press release.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate new financial or operational information presented directly in the filing itself.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- Kristin Taylor (person) — Signatory for the company
- November 4, 2024 (date) — Date of the press release and filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated November 4, 2024, issued by ImmunoPrecise Antibodies Ltd.
What is the filing date of this report?
The filing date of this report is November 4, 2024.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release dated November 4, 2024, is included with this Form 6-K.
Which form does ImmunoPrecise Antibodies Ltd. indicate it files annually?
ImmunoPrecise Antibodies Ltd. indicates it files annual reports under cover of Form 20-F.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed this report on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-11-04 08:54:49
Filing Documents
- press_release_nov_4_2024.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 28KB
- 0000950170-24-120308.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: November 4, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer